Despite improvements in hypertension awareness and treatment, the blood pressure (BP) control rate still remains at around 50%. One of the major determinants of low BP control results from therapeutic inertia of the physician and suboptimal compliance of the patients. Home BP self-measurement and monitoring improves patients' awareness and helps the management of hypertension. Recent technological advances are allowing for accurate measurement and telemonitoring of home BP, with a number of randomized clinical trials demonstrating the efficacy of telemonitoring for BP control. Home BP telemonitoring combined with self-adjustment based on prespecified treatment algorithms has been shown to improve BP control. Additionally, telemonitoring with active intervention by medical professionals has been shown to improve drug compliance and increase the target BP achievement rate. Although nothing can replace the tried and tested doctor-patient relationship in the office, telemonitoring of home BP will be an important tool for treating hypertension in the future.

1.
Egan BM, Zhao Y, Axon RN: US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-2050.
2.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357.
3.
Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al: Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013;3:e003423.
4.
Agarwal R, Bills JE, Hecht TJ, Light RP: Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 2011;57:29-38.
5.
Staessen JA, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G, et al: Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. JAMA 2004;291:955-964.
6.
Omboni S, Ferrari R: The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep 2015;17:535.
7.
McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al: Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA 2014;312:799-808.
8.
McKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S, et al: Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ 2013;346:f3030.
9.
Kim YN, Shin DG, Park S, Lee CH: Randomized clinical trial to assess the effectiveness of remote patient monitoring and physician care in reducing office blood pressure. Hypertens Res 2015;38:491-497.
10.
Omboni S, Guarda A: Impact of home blood pressure telemonitoring and blood pressure control: a meta-analysis of randomized controlled studies. Am J Hypertens 2011;24:989-998.
11.
Omboni S, Gazzola T, Carabelli G, Parati G: Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens 2013;31:455-467; discussion 67-68.
12.
McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al: Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 2010;376:163-172.
13.
Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V, et al: Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med 2011;171:1173-1180.
14.
Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, et al: Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 2008;299:2857-2867.
15.
Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al: Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA 2013;310:46-56.
16.
Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM: Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med 2013;159:185-194.
17.
Imai Y, Obara T, Asamaya K, Ohkubo T: The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. Hypertens Res 2013;36:661-672.
18.
Kario K, Nishizawa M, Hoshide S, Shimpo M, Ishibashi Y, Kunii O, et al: Development of a disaster cardiovascular prevention network. Lancet 2011;378:1125-1127.
19.
Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, et al: Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159-2169.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.